To include your compound in the COVID-19 Resource Center, submit it here.

ITMN to run another Actimmune Phase III

InterMune (ITMN) said it will begin by year end a double-blind, placebo-controlled Phase III trial

Read the full 156 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE